Devices Aim to Identify Those “At Risk” of OIRD

« Back to Industry News

05/06/2017

Medtronic hopes its new study will establish a role for pulse oximetry and capnography in patients on opioid medication.

Patients with Opioid Induced Respiratory Depression (OIRD) experience a decrease in the effectiveness of ventilatory function, an ability to breathe, after opioid administration. Respiratory compromise is a potentially life-threatening, progressive condition negatively impacting a person’s ability to breathe. This condition is rapidly becoming the third-most costly hospital inpatient expense in the U.S., and dramatically increases the likelihood of adverse patient outcomes and cost of patient care.

Not only is respiratory compromise common and dangerous, it has been very difficult to predict. This is where Medtronic clearly hopes it can step in. The company is using two of its diagnostic technologies to identify “at risk” individuals.

Medtronic’s 1,650-patient global study aims to identify individuals at high risk for OIRD. It is the first study to assess the clinical and economic benefits derived from the use of pulse oximetry and capnography, in patients receiving opioid medication on hospital general care floors. The first patient was enrolled in the study at The Ohio State University Wexner Medical Center.

The study is titled PRODIGY (PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY), and is a prospective, multi-center, post-market, global study conducted at 16 sites.

Through the development of a risk assessment scoring tool, the study will seek to identify patients at increased risk for respiratory compromise. It will evaluate hospital ward patients receiving opioids for post-surgical or non-surgical pain who are continuously monitored with capnography and oximetry. The study will also help inform clinicians’ understanding of the true incidence of respiratory compromise, which may be underestimated. The scoring tool will be used at the trial sites, with the goal of wider adoption across more hospitals following completion of the study.

The continuous monitoring of a patient’s oxygen and carbon dioxide levels will also allow PRODIGY to identify other causes of respiratory compromise in patients on the general care ward. Currently, ward patients’ breathing is monitored manually, and typically is no more frequent than every four hours.


Click here to view the full related article.

« Back to Industry News